https://www.jpost.com/science/article-739262
The new treatment has been detailed in a peer-reviewed study, which has been published on Wednesday in the journal PNAS.
The new treatment, using peptides, interacts with the CDK5 enzyme. The CDK5 enzyme is overactive in Alzheimer’s patient’s brains. Fortunately, the peptide has not shown signs of reacting with the essential CDK1 enzyme which shares structural similarities with CDK5.